Collecting blood samples to study biomarkers in pancreatic cancer
Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer
This study is collecting blood samples from patients with pancreatic cancer to see if certain markers in the blood can help improve diagnosis and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05743049 on ClinicalTrials.gov |
What this trial studies
This observational study involves collecting blood samples from patients diagnosed with pancreatic adenocarcinoma to evaluate circulating biomarkers. The goal is to analyze these biomarkers to better understand their role in pancreatic cancer. Participants must be patients at the University of Pennsylvania and provide informed consent. The study aims to gather valuable data that could lead to improved diagnostic and therapeutic strategies for pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a known or presumed diagnosis of pancreatic adenocarcinoma who are patients at the University of Pennsylvania.
Not a fit: Patients with significant psychiatric, social, or medical conditions that could interfere with their ability to participate or provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of pancreatic cancer and lead to better diagnostic tools and treatment options for patients.
How similar studies have performed: While this study focuses on biomarker collection, similar studies have shown promise in understanding cancer biology and improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * The subject must be a patient of the University of Pennsylvania * The subject must be able to provide informed consent * The subject must be 18 years of age or older Exclusion Criteria: . Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Mark O'Hara, MD — Abramson Cancer Center, University of Pennsylvania
- Study coordinator: Liudmila Mazaleuskaya, PhD
- Email: mazali@pennmedicine.upenn.edu
- Phone: 267-455-9141
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.